Survivin expression in ovarian cancer
Aim: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages. Methods: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples. Quantitative real-time PCR was used to estimate survivin...
Gespeichert in:
| Datum: | 2007 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2007
|
| Schriftenreihe: | Experimental Oncology |
| Schlagworte: | |
| Online Zugang: | https://nasplib.isofts.kiev.ua/handle/123456789/138578 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Zitieren: | Survivin expression in ovarian cancer / Z. Liguang, L. Peishu, M. Hongluan, J. Hong, W. Rong, M.S. Wachtel, E.E. Frezza // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 121–125. — Бібліогр.: 26 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
nasplib_isofts_kiev_ua-123456789-138578 |
|---|---|
| record_format |
dspace |
| spelling |
nasplib_isofts_kiev_ua-123456789-1385782025-02-09T15:29:13Z Survivin expression in ovarian cancer Экспрессия сурвивина в ткани при раке яичника Liguang, Z. Peishu, L. Hongluan, M. Hong, J. Rong, W. Wachtel, M.S. Frezza, E.E. Original contributions Aim: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages. Methods: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples. Quantitative real-time PCR was used to estimate survivin mRNA levels in the samples with positive survivin expression. Results: No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors. The survivin mRNA expression rate was positively associated with clinical stage (P = 0.026) and differentiation grade (P = 0.049). There was notably statistically significant difference in the survivin mRNA expression rate dependent on different histological types (serous, mucinous, endometrioid, P = 0.008), but not – dependent on lymph node metastasis (P = 0.921) and ascites (P = 0.87). In tissues with positive expression of survivin, we also found that mean survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian carcinoma tissues (P < 0.001). Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical stages, differentiation grade, lymph node metastasis, but not — with ascites and histological type. Conclusion: Our study suggest that survivin is associated with progression of ovarian carcinoma. Цель: исследовать экспрессию сурвивина в доброкачественных и злокачественных новообразованиях яичника. Методы: экспрессия мРНК сурвивина исследована методом RT-PCR в 114 образах ткани яичника человека. Для установления уровня экспресии мРНК сурвивина применяли количественный PCR в режиме реального времени. Результаты: экспрессия мРНК сурвивина не выявлена в образцах нормальной ткани яичника, но зарегистрирована в 73% случаев рака яичника, 47% случаев серозных опухолей яичника серозного типа и 19% образцов доброкачественных опухолей. Установлена положительная зависимость между уровнем экспрессии мРНК сурвивина и клинической стадией заболевания (P = 0,026), и степенью дифференцировки опухоли (P = 0,049). Выявлена статистически значимая зависимость уровня экспрессии мРНК сурвивина от гистологического типа опухоли (серозного, мукозного, эндометриоидного, P = 0,008) и отсутствие таковой от наличия метастазов в лимфатических узлах (P = 0.921) или асцита (P = 0.87). Также установлено, что средние уровни экспрессии мРНК сурвивина выше при раке яичника, чем в ткани доброкачественных новобразований или серозных опухолей яичника пограничного типа (P < 0,001). При раке яичника высокий уровень экспрессии мРНК сурвивина коррелировал с клинической стадией заболевания, степенью дифференцировки опухолевых клеток, но не коррелировал с гистологическим типом новообразования. Выводы: результаты свидетельствуют о том, что экспрессия сурвивина ассоциирована с прогрессией рака яичника. Ключевые слова: сурвивин, рак яичника, опухолевая прогрессия. We thank several colleagues for collecting clinical materials and Feng Jingbo for the technical assistance. We also thank for Dr. Guo Yongjun and Dr. Chen Bo for their help in preparing the manuscript. 2007 Article Survivin expression in ovarian cancer / Z. Liguang, L. Peishu, M. Hongluan, J. Hong, W. Rong, M.S. Wachtel, E.E. Frezza // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 121–125. — Бібліогр.: 26 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/138578 en Experimental Oncology application/pdf Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Original contributions Original contributions |
| spellingShingle |
Original contributions Original contributions Liguang, Z. Peishu, L. Hongluan, M. Hong, J. Rong, W. Wachtel, M.S. Frezza, E.E. Survivin expression in ovarian cancer Experimental Oncology |
| description |
Aim: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages. Methods: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples. Quantitative real-time PCR was used to estimate survivin mRNA levels in the samples with positive survivin expression. Results: No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors. The survivin mRNA expression rate was positively associated with clinical stage (P = 0.026) and differentiation grade (P = 0.049). There was notably statistically significant difference in the survivin mRNA expression rate dependent on different histological types (serous, mucinous, endometrioid, P = 0.008), but not – dependent on lymph node metastasis (P = 0.921) and ascites (P = 0.87). In tissues with positive expression of survivin, we also found that mean survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian carcinoma tissues (P < 0.001). Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical stages, differentiation grade, lymph node metastasis, but not — with ascites and histological type. Conclusion: Our study suggest that survivin is associated with progression of ovarian carcinoma. |
| format |
Article |
| author |
Liguang, Z. Peishu, L. Hongluan, M. Hong, J. Rong, W. Wachtel, M.S. Frezza, E.E. |
| author_facet |
Liguang, Z. Peishu, L. Hongluan, M. Hong, J. Rong, W. Wachtel, M.S. Frezza, E.E. |
| author_sort |
Liguang, Z. |
| title |
Survivin expression in ovarian cancer |
| title_short |
Survivin expression in ovarian cancer |
| title_full |
Survivin expression in ovarian cancer |
| title_fullStr |
Survivin expression in ovarian cancer |
| title_full_unstemmed |
Survivin expression in ovarian cancer |
| title_sort |
survivin expression in ovarian cancer |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2007 |
| topic_facet |
Original contributions |
| url |
https://nasplib.isofts.kiev.ua/handle/123456789/138578 |
| citation_txt |
Survivin expression in ovarian cancer / Z. Liguang, L. Peishu, M. Hongluan, J. Hong, W. Rong, M.S. Wachtel, E.E. Frezza // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 121–125. — Бібліогр.: 26 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT liguangz survivinexpressioninovariancancer AT peishul survivinexpressioninovariancancer AT hongluanm survivinexpressioninovariancancer AT hongj survivinexpressioninovariancancer AT rongw survivinexpressioninovariancancer AT wachtelms survivinexpressioninovariancancer AT frezzaee survivinexpressioninovariancancer AT liguangz ékspressiâsurvivinavtkaniprirakeâičnika AT peishul ékspressiâsurvivinavtkaniprirakeâičnika AT hongluanm ékspressiâsurvivinavtkaniprirakeâičnika AT hongj ékspressiâsurvivinavtkaniprirakeâičnika AT rongw ékspressiâsurvivinavtkaniprirakeâičnika AT wachtelms ékspressiâsurvivinavtkaniprirakeâičnika AT frezzaee ékspressiâsurvivinavtkaniprirakeâičnika |
| first_indexed |
2025-11-27T10:30:19Z |
| last_indexed |
2025-11-27T10:30:19Z |
| _version_ |
1849939129649856512 |
| fulltext |
Experimental Oncology ���� ��������� ����� ���ne�� ������� ��������� ����� ���ne�� �����ne�� ����� ��� ���
Ovarian cancer occ�pies the place among the
leading ca�ses of death from gynecological cancer.
Altho�gh the �-year s�rvival rate for all stages has
improved recently�� it is still disappointingly low �3�%����
largely beca�se that there is no efficient methods for
diagnosis and therapy [�]. So it is important to search
for a biomarker identifying high risk patients.
S�rvivin is a member of the inhibitor of apoptosis
protein �IAP�� family and has been implicated in both
apoptosis inhibition and cell cycle control [��� 3]. It is
aberrantly expressed in vario�s kinds of cancer cells
b�t is �ndetectable in normal differentiated ad�lt tis-
s�es�� except testis�� thym�s�� and placenta [4]. More-
over�� many st�dies have reported that the expression
rate of s�rvivin in t�mor tiss�es is associated with
t�mor progression and �nfavorable clinicopathologic
variables�� s�ch as poor prognosis�� shorter patient
s�rvival rates and chemoresistance [����].
S�rvivin is expressed in h�man carcinomas�� b�t its
expression levels in tiss�es are different�� that is associ-
ated with the poor o�tcome of patients [�3��4]. Many
st�dies have demonstrated that rate of expression
and s�bcell�lar localization of s�rvivin correlated with
the progression and prognosis of ovarian carcinoma
[����8]. In this st�dy�� we �sed QRT-PCR to analyze
s�rvivin expression levels in benign ovarian t�mors��
ovarian carcinomas of different stages in order to
identify these correlations. It was shown that the high
s�rvivin mRNA expression is implicated in ovarian
carcinoma progression and may serve as a prognostic
marker for ovarian carcinoma patients.
Materials and Methods
Patients and tissue handling. Fresh ovarian tis-
s�es were obtained with Instit�tional Review Board
approved informed consent from patients treated
by the Department of Gynecologic & Obstetrics at
Qil� hospital of Shandong University between De-
cember ���� and ��ly ���6�� and incl�de 63 cases
of ovarian carcinoma�� �� cases of borderline ovarian
carcinoma�� �� cases of benign ovarian t�mor�� and
�� samples of normal ovarian tiss�e from patients
who �nderwent total abdominal hysterectomy with
salpingo-oopherectomy for non-malignant gyneco-
logic disease. The patients ranged in age from �� to
��� years ���.3 ± ��.6 years; median age�� �6 years��.
The staging and grading of t�mors were determined
in accordance with the International Federation of
Gynecology and Obstetrics �FIGO�� criteria ���8��� for
malignant ovarian carcinoma; �8 t�mors were classi-
fied as early stage �I/II�� and 3� — as advanced stage
�III/IV��; 3� cases were at low grade �G��G����� and
33 — at high grade�G3��. Histological types incl�ded
sero�s �n = 4����� m�cino�s �n = ������ and endometrioid
�n = ���. There were 34 cases with lymph node metas-
tasis and 36 cases with ascites. All tiss�e specimens
were immediately frozen in liq�id nitrogen and then
stored in �8� °C �ntil �se.
RNA extraction and reverse transcription. Total
RNA was extracted from frozen tiss�es by the Trizol
reagent �Invitrogen�� USA���� according to the s�pplier’s
survivin expression in ovarian cancer
Z. Liguang1, L. Peishu1, *, M. Hongluan1, J. Hong2, W. Rong2, M.S. Wachtel3, E.E. Frezza4
1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University,
Jinan, Shandong 250012, PR China
2The Key Laboratory of Cardiovascular Remodeling and Function Research,
Qilu Hospital of Shandong University, Jinan, Shandong 250012, PR China
3Department of Pathology, Texas Tech University Health Sciences Center, Lubbock Texas, USA
4Department of General Surgery, Texas Tech University Health Sciences Center, Lubbock Texas, USA
Aim: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages. Methods: We screened
the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples. Quantitative
real-time PCR was used to estimate survivin mRNA levels in the samples with positive survivin expression. Results: No survivin
mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian
carcinomas and 19% of benign ovarian tumors. The survivin mRNA expression rate was positively associated with clinical stage
(P = 0.026) and differentiation grade (P = 0.049). There was notably statistically significant difference in the survivin mRNA
expression rate dependent on different histological types (serous, mucinous, endometrioid, P = 0.008), but not – dependent on
lymph node metastasis (P = 0.921) and ascites (P = 0.87). In tissues with positive expression of survivin, we also found that mean
survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian
carcinoma tissues (P < 0.001). Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical
stages, differentiation grade, lymph node metastasis, but not — with ascites and histological type. Conclusion: Our study suggest
that survivin is associated with progression of ovarian carcinoma.
Key Words: survivin, ovarian carcinoma, progression.
Received: April 12, 2007.
*Correspondence: Fax: (0086) 0531-86920598
E-mail: liguang1229@hotmail.com
Abbreviations used: IAP — inhibitor of apoptosis protein; MDS —
myelodysplastic syndrome; QRT-PCR — quantitative real-time
PCR; RT-PCR — reverse transcription-polymerase chain reaction.
Exp Oncol �����
���� ��� �������
��� Experimental Oncology ���� ��������� ����� ���ne��
protocol. Total RNA �3 μg�� samples were reverse
transcribed to a final vol�me of �� μl�� �sing �� pM
oligo-�dT��-primer �TaKaRa�� �apan���� � mM dNTP mix
�TaKaRa�� �apan���� ��� U reverse transcriptase �Pro-
mega�� USA���� and � × b�ffer 4 μl. RT reactions were
performed on Mastercycler �Eppendorf�� Germany��.
RNA was treated for 3� min at 3�� °C by DNase before
reverse transcription.
RT-PCR analysis survivin mRNA expression in
ovarian tissues. We screened the positive expression
of s�rvivin mRNA by RT-PCR in ��4 ovarian samples.
The cDNA was amplified in a �� μl reaction vol�me
containing � U Taq polymerase �Promega�� USA����
��� μM dNTP�� �.� mM MgCl��� � μl �� × polymerase
chain reaction b�ffer�� and �� mM KCL. Specific pri-
mers for s�rvivin and β-actin were generated �sing
the Primer 3 software and prepared by Invitrogen
Biotech. The seq�ences of the primers are shown in
Table �. All PCRs were performed by Mastercycler
�Eppendorf�� Germany��. The cycling conditions com-
prised a denat�ration step for � min at �� °C�� followed
by 4� cycles of denat�ration ��� °C for 3� s���� anneal-
ing ��3 °C for 3� s�� and extension ���� °C for 3� s��. The
PCR prod�cts were electrophoresed on a �% agarose
gel�� stained with ethidi�m bromide ��.� μg/ml���� and
vis�alized by an UV transill�minator �Alpha Innotech��
USA��.We �sed h�man β-actin as an internal marker.
It was considered positive if PCR prod�ct was ��� bp
by gel electrophoresis.
Table 1. Primers used for PCR
Survivin Antisense CTTTCTCAACGACCACCG 110 bp NM001168.2sense GTAGGTGACGGGGTGAC
β-Actin Antisense GTTGCGTTACACCCTTTC 152 bp NM001101.2sense CTGTCACCTTCACCGTTC
QRT-PCR analysis survivin mRNA expression
levels in ovarian tisssues. QRT-PCR was �sed to
determine relative s�rvivin mRNA expression levels in
�� cases with s�rvivin �+�� ovarian tiss�es. QRT-PCR
analysis was performed on Light Cycler �Roche Ap-
plied Science�� USA�� and on a vol�me of �� μl contain-
ing � μl of cDNA�� �� μl of �� × SYBR Green PCR Master
Mix �TaKaRa�� �apan���� �.� μl of each primer ��� pM����
and 8 μl of DEPC-treated water. Primers for s�rvivin
and β-actin were same as those �sed for RT-PCR.
The program for detection s�rvivin was set at �� °C for
�� s�� q�antification program ��� °C for � s�� �6 °C for
� s�� and ��� °C for � s�� 83 °C for � s�� which was repeated
�� times�� a melting c�rve program ��� °C for � s and
6�°C for 3� s�� ��°C with a heating rate of �.� °C for � s
and contin�o�s fl�orescence meas�rement���� and a
cooling step to 4� °C for 3� s. The program for detected
β-actin was set at �� °C for �� s�� q�antification ��� °C
for � s�� �3 °C for � s�� and ��� °C for �� s�� which was
repeated �� times�� a melting c�rve program ��� °C for
� s and 6� °C for 3� s�� �� °C with a heating rate of �.� °C
for � s and contin�o�s fl�orescence meas�rement����
and a cooling step to 4� °C for 3� s. A standard c�rve of
cycle thresholds �sing serial dil�tions of cDNA samples
were �sed to calc�late the relative ab�ndance. Melting
c�rve analysis was performed to confirm prod�ction of
a single prod�ct in each reaction. The specificity of the
amplification prod�cts was verified f�rther by s�bject-
ing the amplification prod�cts to electrophoresis on a
�% agarose gel. S�rvivin mRNA expression was nor-
malized to the expressed ho�sekeeping gene β-actin.
The data was analyzed with Light Cycle software 4.�
�Roche Applied Science�� USA��.
Statistical analysis. All statistical analyses were
performed with the SPSS ��.� � software package
for Windows �SPSS Inc�� Chicago�� IL��. The correlation
between s�rvivin expression and clinicopathologic
feat�res was statistically analyzed with the Chi-sq�are
test and Fisher’s exact test. St�dent’s two-tailed t-test
was �sed to compare data between two gro�ps. One-
way analysis of variance and Bonferroni’s correction
were �sed to compare data between three or more
gro�ps. P-val�e < �.�� was considered statistically
significant.
results
RT-PCR analysis survivin mRNA expression in
ovarian tissues. RT-PCR analysis showed that there
were �� cases with positive s�rvivin mRNA expres-
sion from ��4 ovarian tiss�e samples�� incl�ding zero
in normal ovarian tiss�es�� 46 ���3%�� in the 63 cases
of ovarian carcinomas�� 8 �4��%�� in the �� cases of
borderline ovarian carcinomas�� 4 ���%�� in �� cases of
benign ovarian t�mors �Table ��� Fig. ��� Fig. ��� a��. The
data on relationship between the vario�s clinicopatho-
logic feat�res and s�rvivin mRNA expression rate are
described in Table �. A significant positive correlation
�P = �.��6�� was observed between s�rvivin mRNA
expression rate and histological grade �Fig. ��� b��. Of
the 3� low-grade �G��G��� t�mors�� �8 �6�%�� showed
s�rvivin mRNA expression. In contrast�� �� �84%�� of
33 high-grade t�mors �G3�� were positive for s�rvivin
mRNA expression. F�rthermore�� a significant cor-
relation �P = �.�4��� became evident between s�rvivin
expression and clinical stage of the disease �Fig. ��� c��.
��� �6�%�� cases with positive s�rvivin expression were
related to stage I/II�� and �� �8�%�� cases to stage III/IV.
The s�rvivin expression rate in ovarian carcinomas was
associated with histological type �P = �.��8�� Fig. ��� d ����
b�t no correlation was fo�nd between s�rvivin expres-
sion and lymph node metastasis �P = �.����� Fig. ��� e��
or ascites �P = �.8���� Fig. ��� f�� .
Fig. 1. S�rvivin mRNA expression in ovarian tiss�es analyzed
by RT-PCR. NOV: normal ovarian carcinoma�� BOVT: benign ova-
rian t�mor�� BOVC: borderline ovarian carcinoma�� OVC: ovarian
carcinoma. Actin — ��� bp�� s�rvivin — ��� bp
Experimental Oncology ���� ��������� ����� ���ne�� ��3���� ��������� ����� ���ne�� ��3��ne�� ��3�� ��3 ��3
Fig. 2. The rate of s�rvivin expression in ovarian tiss�e samples
dependent on type of t�mor �a�� NOV: normal ovarian carcinoma��
BOVT: benign ovarian t�mor�� BOVC: borderline ovarian carcinoma��
OVC: ovarian carcinoma��; differentiation grade �b��; clinical stage �c��;
histological type �d��; lymph node metastasis �e�� and ascites �f��
Table 2. Expression of survivin mRNA in ovarian tissue samples
Sample Number
of patients
Positive survivin
expression (%) P-value
Normal ovarian tissue 11 0 (0%)
Benign ovarian tumor 21 4 (19%)
Borderline ovarian carcinoma 19 9 (47%)
Ovarian carcinoma 63 46 (73%)
Grade: 0.026
G1–G2 30 18 (60%)
G3 33 28 (84%)
FIGO stage:
0.049I–II 28 17 (60%)
III–IV 35 29 (82%)
Histological type:
0.008serous 42 35 (76%)
mucinous 12 8 (66%)
endometrioid 9 3 (33.3%)
Lymph node metastasis: 0.921
Yes 34 25 (73%)
No 29 21 (72%)
Ascites: 0.87
yes 36 26 (72%)
No 27 20 (74%)
QRT-PCR analysis survivin mRNA expression
levels. QRT-PCR was �sed to determine relative expres-
sion levels of the s�rvivin gene in �� cases with s�rvivin
�+�� ovarian tiss�es. The res�lts demonstrated that higher
levels of s�rvivin/β-actin mRNA expression in ovarian car-
cinoma ��.���� ± �.��486�� than that in borderline ovarian
carcinoma tiss�es ��.���� ± �.���88�� and benign ovarian
t�mor tiss�es ��.����� ± �.�������. There was statistical
difference among them �P < �.���� Fig. 3�� a��. The res�lts
also demonstrated that there was significant difference of
mean s�rvivin/ β-actin mRNA expression levels between
G��G� and G3 in ovarian carcinoma ��.���4 ± �.��348
vers�s �.��4� ± �.���33�� P = �.�4��� Fig. 3�� b��. In advanced
stage �III/IV�� cancers�� the mean s�rvivin/β-actin mRNA
expression levels were higher than that in early-stage �I/II��
cancers ��.���4 ± �.��3�6 vers�s �.��4� ± �.���3���� P =
�.�4��� Fig. 3�� c��. F�rthermore�� we fo�nd that the mean
s�rvivin mRNA levels were higher in cases with lymph
node metastasis than that witho�t lymph node metastasis
��.���3 ± �.��3�� vers�s �.��44 ± �.���46�� P = �.�3���
Fig. 3�� d��. No statistical difference �P > �.���� Fig. 3�� e��
was identified in s�rvivin expression among sero�s can-
cers�� endometrioid and m�cino�s�� no statistic difference
�P > �.���� Fig. 3�� f�� to ascites either �Table 3��.
Fig. 3. S�rvivin/actin mRNA expression levels in ovarian tiss�es
meas�red by real time PCR depenedent on on type of t�mor �a��
NOV: normal ovarian carcinoma�� BOVT: benign ovarian t�mor��
BOVC: borderline ovarian carcinoma�� OVC: ovarian carcinoma��;
differentiation grade �b��; clinical stage �c��; histological type �d��;
lymph node metastasis �e�� and ascites �f��
��4 Experimental Oncology ���� ��������� ����� ���ne��
Table 3. Survivin/β-actin mRNA expression levels
Sample Survivin/β-actin mRNA ex-
pression levels (means ± SD) P-value
Benign ovarian tumor 0.0007 ± 0.00011
Borderline ovarian carcinoma 0.0055 ± 0.00188 < 0.001
Ovarian carcinoma 0.0122 ± 0.00486
Grade:
G1–G2 0.0104 ± 0.00348 0.041
G3 0.0142 ± 0.00533
FIGO stage:
I–II 0.0104 ± 0.00316 0.041
III–IV 0.0141 ± 0.00537
Histological type:
serous 0.0133 ± 0.00525 0.673 (s vs m)
mucinous 0.0123 ± 0.00478 0.600 (s vs e)
endometrioid 0.0177 ± 0.00562 0.856 (m vs e)
Lymphonode metastasis:
Yes 0.0103 ± 0.00302 0.031
No 0.0144 ± 0.00546
Ascites:
yes 0.0137 ± 0.00518
no 0.0125 ± 0.00526 0.563
discussion
Ovarian carcinoma is among the most common
female cancers and the leading ca�se of death from
gynecologic malignancy in the world. Altho�gh the
clinical and histological prognostic factors �e. g. t�mor
grade and clinical stage�� had been reported to be of
prognostic significance in ovarian cancer [��]�� it is
conceivable that the assessment of biochemical factors
more strictly related to t�mor cell biology and intrinsic
aggressiveness co�ld help identifying high-risk patients
and facilitating management of this disease.
Cell proliferation and cell death pathways meet at a
pivotal crossroad�� cr�cial to maintain normal homeo-
stasis and to eliminate dangero�s cells before they
start dividing. S�rvivin is an intrig�ing and fascinating
protein at this crossroad that interfaces life and death��
thro�gh its d�al role in facilitating cell division and
enco�ntering apoptosis [��]. S�rvivin promotes cell
proliferation and enhances angiogenesis�� it may play
an important role in protecting abnormal cells from
apoptosis d�ring cell division�� which contrib�tes to
t�mor development and prognosis [����3].
Several st�dies had shown that s�rvivin mRNA ex-
pression levels correlated with the prognosis in s�ch
carcinomas as osteosarcoma and myelodysplastic
syndrome [�3��4]. Only the expression rate of s�rvivin
has been reported to be associated with progress and
prognosis of ovarian carcinoma in some literat�res
[����8]�� b�t little is known abo�t the relationship bet-
ween the expression levels of s�rvivin and prognosis
of ovarian carcinoma.
In o�r experiment we testified that the rate of
s�rvivin expression is associated with progression of
ovarian carcinoma and some other parameters �FIGO
stage�� differentiation grade�� and histological type��.
Moreover�� we fo�nd that s�rvivin expression levels
were different in s�rvivin positive tiss�es. S�rvivin ex-
pression levels were the highest in ovarian carcinomas��
and there were the lowest s�rvivin expression levels in
benign ovarian t�mor tiss�es. F�rthermore�� s�rvivin
expression levels are associated with the FIGO stage��
grade�� and lymph node metastasis�� b�t not with ascites
and histological type in ovarian carcinoma.
In this st�dy we determined not only whether s�r-
vivin gene was expressed or not�� b�t also the levels of
s�rvivin expression in ovarian carcinoma. One can �se
real time PCR to detect the mRNA expression of ova-
rian tiss�es by biopsy. F�rthermore�� s�rvivin is �nder
st�dy as a novel target for the treatment of cancer��
and its expression may be reg�lated by different ap-
proaches [�4��6].
The relationships between s�rvivin expression
levels and the s�rvival rate or the reaction to chemo-
therapy of patients with ovarian carcinoma were not
showed in the present st�dy�� beca�se of the lack of the
follow-�p. F�rther long-term follow-�p st�dies wo�ld
be done in f�t�re to address these q�estions.
acknowledgeMent
We thank several colleag�es for collecting clinical
materials and Feng �ingbo for the technical assistance.
We also thank for Dr. G�o Yongj�n and Dr. Chen Bo for
their help in preparing the man�script.
reFerences
1. Bjorge T, Engeland A, Sundfor K, Trope CG. Prognosis
of 2800 patients with epithelial ovarian cancer diagnosed dur-
ing 1975–94 and treated at the Norwegian Radium Hospital.
Anta Obstet Gynecol Scand 1998; 77: 777–81.
2. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction
of apoptosis and inhibition of cell proliferation by survivin gene
targeting. J Biol Chem 1998; 273: 11177–82.
3. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchi-
sio PC, Altieri DC. Control of apoptosis and mitotic spindle
checkpoint by survivin. Nature 1998; 396: 580–4.
4. Ambmsini G, Adids C, Alticri DC. A novel antiapoptosis
gene survivin expressed in cancer and lymphoma. Nat Med
1997; 3: 917–21.
5. Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sar-
gent DJ, Cheville J et al. Characterization of antigen processing
machinery and survivin expression in tonsillar squamous cell
carcinoma. Cancer 2003; 97: 2203–11.
6. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehr-
born CG, Slawin KM et al. Survivin expression is associated
with features of biologically aggressive prostate carcinoma.
Cancer 2004; 100: 751–7.
7. Saxena A, Yashar C, Taylor DD, Gercel-Taylor C. Cellu-
lar response to chemotherapy and radiation in cervical cancer.
Am J Obstet Gynecol 2005; 192: 1399–403.
8. Muzio LL, Pannone G, Staibano S, Mignogna MD,
Rubini C, Mariggio MA. Survivin expression in oral squamous
cell carcinoma. Br J Cancer 2003; 89: 2244–8.
9. Rodel F, Hoffmann J, Distel L, Herrmann M, Nois-
ternig T, Papadopoulos T. Survivin as a radioresistance factor
and prognostic and therapeutic target for radiotherapy in rectal
cancer. Cancer Res 2005; 65: 4881–7.
10. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D,
Fujimoto K, Wada M, Miyatake S, Imamura M. Survivin ex-
pression is a prognostic marker in pancreatic cancer patients.
Surgery 2004; 136: 443–8.
11. Lee JP, Chang KH, Han JH, Ryu HS. Survivin, a novel
anti-apoptosis inhibitor, expression in uterine cervical cancer
and relationship with prognostic factors. Int J Gynecol Cancer
2005; 15: 113–9.
12. Mizutani K, Matsumoto K, Hasegawa N, Deguchi T,
Nozawa Y. Expression of clusterin, XIAP and survivin, and
their changes by camptothecin (CPT) treatment in CPT-
Experimental Oncology ���� ��������� ����� ���ne�� ������� ��������� ����� ���ne�� �����ne�� ����� ��� ���
resistant PC-3 and CPT-sensitive LNCaP cells. Exp Oncol
2006; 28: 209–15.
13. Gianelli U, Fracchiolla NS, Cortelezzi A. Survivin
expression in “low-risk” and “high-risk” myelodysplastic
syndromes. Ann Hematol 2007; 86: 185–9.
14. Osaka E, Suzuki T, Osaka S. Survivin as a prognostic
factor for osteosarcoma patients. Acta Histochem Cytochem
2006; 39: 95–100.
15. Fernandina G, Legge F, Martinelli E, Ranelletti FO,
Zannoni GF. Survivin expression in ovarian cancer and its
correlation with clinicopathological, surgical and apoptosis-
related parameters. Br J Cancer 2005; 92: 271–7.
16. Tringler B, Lehner R, Shroyer AL, Shroyer KR. Im-
munohistochemical localization of survivin in serous tumors
of the ovary. Appl Immunohistochem Mol Morphol 2004;
12: 40–3.
17. Kleinberg L, Florenes VA, Silins I, Haug K. Nuclear
expression of survivin is associated with improved survival in
metastatic ovarian carcinoma. Cancer 2007; 109: 228–38.
18. Cohen C, Lohmann CM, Cotsonis G, Lawson D,
Santoianni R. Survivin expression in ovarian carcino-
ma: correlation with apoptotic markers and prognosis.
Mod Pathol 2003; 16: 574–83.
19. Hoskins WJ, Perez CA, Young RC. Principles and
practice of gynecology. Oncology 2000; 33: 1005–7.
20. Koochekpour S, Zerfaoui M,Yousief Z,Ouhtit A, Ma-
trougui K, Bengrine A. Survivin is not only a death encounter
but also a survival protein for invading tumor cells. Front Biosci
2007; 12: 1260–70.
21. Duffy MJ, O’donovan N, Brennan DJ, Gallagher WM,
Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett
2007; Epub ahead of print.
22. Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH,
Kim HS, Choi SK, Rew JS, Park CS, Kim SJ. Expression of
survivin in gastric cancer and its relationship with tumor an-
giogenesis. Eur J Gastroenterol Hepatol 2006; 18: 957–63.
23. Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN,
Fu LA, He XS, Ma FC, Wang XL. Survivin expression and its
relation with proliferation, apoptosis, and angiogenesis in brain
gliomas. Cancer 2005; 104: 2775–83.
24. Faqing T, Zhi H, Liqun Y, Min T, Huanhua G, Xiyun D,
Ya C. Epstein-Barr virus LMP1 initiates cell proliferation and
apoptosis inhibition via regulating expression of survivin in
nasopharyngeal carcinoma. Exp Oncol 2005; 27: 96–101.
25. Coma S, Noe V, Lavarino C, Adan J, Rivas M, Lopez-
Matas M, Pagan R, Mitjans F, Vilaro S, Piulats J, Ciudad CJ.
Use of siRNAs and antisense oligonucleotides against survivin
RNA to inhibit steps leading to tumor angiogenesis. Oligo-
nucleotides 2004; 14: 100–13.
26. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J,
Binderup L, Brattain MG. Differential regulation of survivin
expression and apoptosis by vitamin D3 compounds in two
isogenic MCF-7 breast cancer cell sublines.Oncogene 2005;
24: 1385–95.
Экспрессия сурвивина в ткани при раке яичника
Цель: исследовать экспрессию сурвивина в доброкачественных и злокачественных новообразованиях яичника. Методы: экспрес-
сия мРНК сурвивина исследована методом RT-PCR в 114 образ�ах ткани яичника человека.�ля установления уровня экспресииRT-PCR в 114 образ�ах ткани яичника человека.�ля установления уровня экспресии-PCR в 114 образ�ах ткани яичника человека.�ля установления уровня экспресииPCR в 114 образ�ах ткани яичника человека.�ля установления уровня экспресиив 114 образ�ах ткани яичника человека. �ля установления уровня экспресии
мРНК сурвивина применяли количественный PCR в режиме реального времени. Результаты: экспрессия мРНК сурвивина
не выявлена в образ�ах нормальной ткани яичника, но зарегистрирована в 73% случаев рака яичника, 47% случаев серозных
опухолей яичника серозного типа и 19% образ�ов доброкачественных опухолей. Установлена положительная зависимость между
уровнем экспрессии мРНК сурвивина и клинической стадией заболевания (P = 0,026), и степенью дифферен�ировки опухоли
(P = 0,049). Выявлена статистически значимая зависимость уровня экспрессии мРНК сурвивина от гистологического типа
опухоли (серозного, мукозного, эндометриоидного, P = 0,008) и отсутствие таковой от наличия метастазов в лимфатических
узлах (P = 0.921) или ас�ита (P = 0.87). Также установлено, что средние уровни экспрессии мРНК сурвивина выше при раке
яичника, чем в ткани доброкачественных новобразований или серозных опухолей яичника пограничного типа (P < 0,001).
При раке яичника высокий уровень экспрессии мРНК сурвивина коррелировал с клинической стадией заболевания, степенью
дифферен�ировки опухолевых клеток, но не коррелировал с гистологическим типом новообразования. Выводы: результаты
свидетельствуют о том, что экспрессия сурвивина ассо�иирована с прогрессией рака яичника.
Ключевые слова: сурвивин, рак яичника, опухолевая прогрессия.
Copyright © Experimental Oncology, 2007
|